Dermata Therapeutics faces Nasdaq delisting for minimum bid price; plans hearing

Dermata Therapeutics, Inc.

Regained compliance with Nasdaq stockholders' equity requirement on May 14, 2025.
Received notice of non-compliance with $1.00 minimum bid price; securities subject to delisting.
Reverse stock split within past year triggers accelerated delisting; suspension possible May 23, 2025.
Company plans to request hearing by May 21, 2025 to stay suspension pending panel decision.
No assurance compliance plan will be accepted; delisting risk remains if plan fails.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.